Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6421 AL 6435

Action of estrogens in the aging brain: dementia and cognitive aging

Henderson VW.

Biochim Biophys Acta. 2010 Oct;1800(10):1077-83. doi: 10.1016/j.bbagen.2009.11.005. Epub 2009 Nov 12.

Mitochondrial mechanisms of estrogen neuroprotection

Simpkins JW, Yi KD, Yang SH, Dykens JA.

Biochim Biophys Acta. 2010 Oct;1800(10):1113-20. doi: 10.1016/j.bbagen.2009.11.013. Epub 2009 Nov 26.

Impaired spatial learning and unaltered neurogenesis in a transgenic model of Alzheimer's disease after oral aluminum exposure

Ribes D, Colomina MT, Vicens P, Domingo JL.

Curr Alzheimer Res. 2010 Aug;7(5):401-8. doi: 10.2174/156720510791383840.

Biochemical and histochemical comparison of cholinesterases in normal and Alzheimer brain tissues

Darvesh S, Reid GA, Martin E.

Curr Alzheimer Res. 2010 Aug;7(5):386-400. doi: 10.2174/156720510791383868.

Colostral proline-rich polypeptides--immunoregulatory properties and prospects of therapeutic use in Alzheimer's disease

Janusz M, Zabłocka A.

Curr Alzheimer Res. 2010 Jun;7(4):323-33. doi: 10.2174/156720510791162377.

Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid

Frisardi V, Solfrizzi V, Imbimbo PB, Capurso C, D'Introno A, Colacicco AM, Vendemiale G, Seripa D, Pilotto A, Capurso A, Panza F.

Curr Alzheimer Res. 2010 Feb;7(1):40-55. doi: 10.2174/156720510790274400.

Targeting p38 MAPK pathway for the treatment of Alzheimer's disease

Munoz L, Ammit AJ.

Neuropharmacology. 2010 Mar;58(3):561-8. doi: 10.1016/j.neuropharm.2009.11.010. Epub 2009 Dec 4.

Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease

Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT.

Clin Drug Investig. 2010;30(1):41-9. doi: 10.2165/11531270-000000000-00000.

Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models

Wisniewski T, Boutajangout A.

Brain Struct Funct. 2010 Mar;214(2-3):201-18. doi: 10.1007/s00429-009-0236-2. Epub 2009 Dec 10.

gamma-Secretase as a therapeutic target in Alzheimer's disease

Guardia-Laguarta C, Pera M, Lleó A.

Curr Drug Targets. 2010 Apr;11(4):506-17. doi: 10.2174/138945010790980349.

Neurobiological effects of Hyperforin and its potential in Alzheimer's disease therapy

Griffith TN, Varela-Nallar L, Dinamarca MC, Inestrosa NC.

Curr Med Chem. 2010;17(5):391-406. doi: 10.2174/092986710790226156.

Are omega-3 fatty acids options for prevention and treatment of cognitive decline and dementia?

Cederholm T, Palmblad J.

Curr Opin Clin Nutr Metab Care. 2010 Mar;13(2):150-5. doi: 10.1097/MCO.0b013e328335c40b.

Inhibition of double-stranded RNA-dependent protein kinase strongly decreases cytokine production and release in peripheral blood mononuclear cells from patients with Alzheimer's disease

Couturier J, Page G, Morel M, Gontier C, Claude J, Pontcharraud R, Fauconneau B, Paccalin M.

J Alzheimers Dis. 2010;21(4):1217-31. doi: 10.3233/jad-2010-100258.

Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy?

Trepanier CH, Milgram NW.

J Alzheimers Dis. 2010;21(4):1089-99. doi: 10.3233/jad-2010-090667.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias